Eli Lilly and Company
Financials
Valuation Metrics
Eli Lilly and Company's Market Cap is $999.79B. At end of 2025 it was $963.46B. Ranked #12 of 3,112 in US market (top 0.4%), #3 of 1,667 on NYSE (top 0.2%), #1 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 0.4%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $999.79B | US#12/3,112 Sec#1/269 |
| Revenue | $72.25B | US#90/3,112 Sec#2/269 |
| Net Income | $25.27B | US#15/3,112 Sec#1/269 |
| Total Assets | $116.58B | US#157/3,112 Sec#7/269 |
| Net Assets | $31.20B | US#161/3,112 Sec#11/269 |
| Employees | 50,000 | US#170/3,112 Sec#6/269 |
| Value | ||
| P/E | 39.56x | US#1,691/3,112 Sec#54/269 |
| P/B | 32.05x | US#2,889/3,112 Sec#243/269 |
| PEG | 0.24x | US#356/3,112 Sec#17/269 |
| P/S | 13.84x | US#2,740/3,112 Sec#133/269 |
| EV/EBITDA | 31.02x | US#2,188/3,112 Sec#68/269 |
| FCF Yield | 1.36% | US#2,076/3,112 Sec#73/269 |
| Profitability | ||
| ROE | 81.01% | US#54/3,112 Sec#8/269 |
| ROA | 21.68% | US#75/3,112 Sec#17/269 |
| Op. Margin | 45.87% | US#149/3,112 Sec#6/269 |
| Revenue Growth | 55.55% | US#269/3,112 Sec#52/269 |
| Earnings Growth | 168.04% | US#232/3,112 Sec#9/269 |
| Financial Health | ||
| Debt Ratio | 273.67% | US#2,054/3,112 Sec#217/269 |
| Total Debt | $43.37B | US#106/3,112 Sec#7/269 |
| FCF | $13.58B | US#47/3,112 Sec#5/269 |
| Cash | $5.14B | US#192/3,112 Sec#12/269 |
| Current Ratio | 1.50x | US#1,669/3,112 Sec#245/269 |
| Net Debt/EBITDA | 1.14x | US#1,074/3,112 Sec#51/269 |
| Dividend | ||
| Div. Yield | 0.56% | US#1,488/3,112 Sec#22/269 |
| Div. Growth | 15.36% | US#335/3,112 Sec#4/269 |
| Performance | ||
| 1Y Return | 47.86% | US#815/3,112 Sec#125/269 |
| 1M Return | -7.64% | US#2,459/3,112 Sec#146/269 |
| From 52W High | -10.27% | US#1,070/3,112 Sec#55/269 |
| 1Y MDD | -23.64% | US#937/3,112 Sec#50/269 |
| Trading | ||
| Volume | 2,493,796 shares | US#740/3,112 Sec#66/269 |
| Trading Value | $2.82B | US#24/3,112 Sec#1/269 |
| Per Share | ||
| EPS | $22.98 | US#61/3,112 Sec#4/269 |
| BPS | $29.55 | US#877/3,112 Sec#19/269 |
Company Info
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.